BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trotter JF. Sirolimus in liver transplantation. Transplant Proc. 2003;35:193S-200S. [PMID: 12742496 DOI: 10.1016/S0041-1345(03)00234-3] [Cited by in Crossref: 91] [Cited by in F6Publishing: 15] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Di Zazzo A, Kheirkhah A, Abud TB, Goyal S, Dana R. Management of high-risk corneal transplantation. Surv Ophthalmol 2017;62:816-27. [PMID: 28012874 DOI: 10.1016/j.survophthal.2016.12.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 9.2] [Reference Citation Analysis]
2 Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109:3108-3114. [PMID: 17138818 DOI: 10.1182/blood-2006-09-046219] [Cited by in Crossref: 146] [Cited by in F6Publishing: 131] [Article Influence: 10.4] [Reference Citation Analysis]
3 Chen KD, Wang CC, Tsai MC, Wu CH, Yang HJ, Chen LY, Nakano T, Goto S, Huang KT, Hu TH. Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma. Cell Death Dis. 2014;5:e1244. [PMID: 24853422 DOI: 10.1038/cddis.2014.212] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
4 Abud TB, Di Zazzo A, Kheirkhah A, Dana R. Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation. J Ophthalmic Vis Res 2017;12:81-92. [PMID: 28299010 DOI: 10.4103/2008-322X.200156] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
5 Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, Snyder D, Pullarkat V, Kogut N, Rosenthal J, Smith E, Karanes C, O'Donnell M, Krishnan AY, Senitzer D, Forman SJ. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010;115:1098-105. [PMID: 19965688 DOI: 10.1182/blood-2009-03-207563] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis]
6 Qi WX, Huang YJ, Yao Y, Shen Z, Min DL. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis. PLoS One 2013;8:e65166. [PMID: 23785409 DOI: 10.1371/journal.pone.0065166] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
7 Asthana S, Toso C, Meeberg G, Bigam DL, Mason A, Shapiro J, Kneteman NM. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011;25:28-34. [PMID: 21258665 DOI: 10.1155/2011/201019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
8 Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol. 2005;139:2-10. [PMID: 15606606 DOI: 10.1111/j.1365-2249.2005.02662.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
9 Moon DB, Lee SG. Liver transplantation. Gut Liver. 2009;3:145-165. [PMID: 20431740 DOI: 10.5009/gnl.2009.3.3.145] [Cited by in Crossref: 54] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
10 Campsen J, Zimmerman MA, Mandell S, Kaplan M, Kam I. A Decade of Experience Using mTor Inhibitors in Liver Transplantation. J Transplant. 2011;2011:913094. [PMID: 21461386 DOI: 10.1155/2011/913094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
11 Chen KD, Lin CC, Tsai MC, Huang KT, Chiu KW. Tumor microenvironment mediated by suppression of autophagic flux drives liver malignancy. Biomed J. 2018;41:163-168. [PMID: 30080656 DOI: 10.1016/j.bj.2018.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
12 Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112:4425-4431. [PMID: 18776081 DOI: 10.1182/blood-2008-07-169342] [Cited by in Crossref: 111] [Cited by in F6Publishing: 86] [Article Influence: 8.5] [Reference Citation Analysis]
13 Furlong T, Kiem HP, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K, Flowers ME, Mielcarek M, Nash RA, Storb R, Martin PJ. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008;14:531-7. [PMID: 18410895 DOI: 10.1016/j.bbmt.2008.02.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
14 Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol. 2008;2:803-816. [PMID: 19090740 DOI: 10.1586/17474124.2.6.803] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 5.3] [Reference Citation Analysis]
15 Neuberger J. Developments in liver transplantation. Gut 2004;53:759-68. [PMID: 15082598 DOI: 10.1136/gut.2003.024927] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]